ENDRA Life Sciences
NDRA
5 hedge funds and large institutions have $156K invested in ENDRA Life Sciences in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% less ownership
Funds ownership: 0% → 0% (-0%)
38% less funds holding
Funds holding: 8 → 5 (-3)
42% less capital invested
Capital invested by funds: $268K → $156K (-$111K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$52.1K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$15.9K |
| 3 |
HF
HRT Financial
New York
|
-$14K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$10.7K |
| 5 |
WAM
Worth Asset Management
Dallas,
Texas
|
-$938 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $55.3K | -$10.7K | -5 | -15% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $43.2K | +$15K | +7 | +47% |
|
|
NA
3
NewEdge Advisors
New Orleans,
Louisiana
| $35.6K | – | – | – |
|
4
Renaissance Technologies
New York
| $11K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $8.24K | +$6.41K | +3 | +300% |
|
|
VNA
6
Valley National Advisers
Bethlehem,
Pennsylvania
| $1K | – | – | – |
|
7
JP Morgan Chase
New York
| $883 | – | – | – |
|
8
Morgan Stanley
New York
| $867 | – | – | – |
|
9
BlackRock
New York
| $114 | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $61 | – | – | – |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$52.1K | -21 | Closed |
|
|
HF
12
HRT Financial
New York
| – | -$14K | -6 | Closed |
|
|
TSS
13
Two Sigma Securities
New York
| – | -$15.9K | -6 | Closed |
|
|
WAM
14
Worth Asset Management
Dallas,
Texas
| – | -$938 | – | – |
|
NDRA Hedge Fund Activity: Q3 2023 in Review
5 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in ENDRA Life Sciences (NDRA) for Q3 2023, worth a combined $156K — down 42% from $268K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NDRA and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Vanguard Group, adding an estimated $15K. The largest seller was Citadel Advisors, exiting entirely with an estimated $52.1K sold.
- 5 institutional investors held ENDRA Life Sciences (NDRA) as of Q3 2023, down from 8 in Q2 2023.
- Funds reported $156K of ENDRA Life Sciences stock for Q3 2023, down 42% quarter-over-quarter.
- 0 funds opened new ENDRA Life Sciences positions in Q3 2023 and 3 closed out, a net change of -3 holders.
- The largest ENDRA Life Sciences buyer in Q3 2023 was Vanguard Group, an estimated $15K added.
- The largest ENDRA Life Sciences seller in Q3 2023 was Citadel Advisors, an estimated $52.1K sold.
Based on aggregated 13F filings for Q3 2023.